PCAC July 2026 Meeting: What Physicians Should Watch for on Compounding Peptides

Why PCAC Matters

The Pharmacy Compounding Advisory Committee (PCAC) is the FDA advisory body that evaluates substances for potential inclusion on the 503A bulk drug substances list. Its recommendations directly shape what compounding pharmacies can legally prepare — and, by extension, what therapies practicing physicians can actually prescribe through compounding channels.

For peptide-oriented practice, PCAC meetings are among the most consequential regulatory events of the year. The April 2026 action was a major reshaping event, and the next scheduled cycle extends that regulatory evolution.

 

What PCAC Meetings Actually Do

PCAC functions as an advisory body. Its process typically involves:

• FDA staff preparation of substance-by-substance evaluations
• Public comment periods where interested parties submit written testimony
• Public meetings where committee members discuss each substance
• Voting on recommendations (include, not include, continue review)
• FDA final action following committee recommendation (FDA is not bound by the committee’s vote but typically considers it)

The meetings themselves are public — physicians can attend, submit comments, and in some cases speak during public comment periods.

 

Substances to Watch in July 2026

For the July 2026 cycle, several categories of substance are likely on or near the agenda:

Peptide bioregulators. Substances like Epitalon and Testagen have been through multiple review cycles; their July 2026 status deserves watching.

Short-chain peptides with established clinical practice. BPC-157, TB-500, and related compounds have had extensive compounding-pharmacy use and have been under evaluation.

Emerging substances. Compounds that have entered the clinical peptide conversation more recently — some will face initial review.

Previously denied substances with new evidence. Substances that were denied earlier may return with additional safety or efficacy evidence.

[Semaglutide](https://newtropin.com/peptides/semaglutide/) and [tirzepatide](https://newtropin.com/peptides/tirzepatide/) compounding framework. The relationship between shortage-related compounding and formal 503A status remains in flux and may get further PCAC attention.

 

How Physicians Should Engage

Practicing physicians have several legitimate avenues for engagement with the PCAC process:

Written public comment. Submitted during defined comment periods, written testimony is part of the public record. Physician comments reflecting real-world clinical experience with a substance carry specific weight.

Professional association engagement. Physician specialty societies sometimes submit coordinated comments. Individual participation through these channels can amplify reach.

Direct meeting attendance. Public meetings allow physicians to be present and, in some cases, address the committee directly.

Staying informed. Even without active submission, tracking PCAC actions ensures that practice adjustments align with the evolving framework.

 

What Testimony Moves the Needle

From the FDA’s framing, PCAC evaluations consider:

• Safety profile of the substance
• Effectiveness evidence for proposed use
• Historical use and clinical experience
• Available alternatives (whether FDA-approved products already cover the use)
• Manufacturing and quality considerations

Physician testimony that concretely addresses clinical experience — with specific patient populations, specific responses, and specific alternatives considered — tends to be more useful than general advocacy.

 

What Patients Should Know

For patients asking about the July 2026 meeting:

• The meeting will affect what peptide substances are accessible through legitimate 503A compounding going forward
• Changes from the meeting typically take effect in the months following final FDA action
• Patients on active peptide protocols should watch for communication from their prescribing physician and compounding pharmacy about any substance-specific changes
• The process is public; patients can also submit their own comments if motivated to do so

 

Preparing Your Practice

In the weeks leading up to any PCAC meeting with peptide substances on the agenda:

• Audit your peptide formulary against the anticipated substances under review
• Identify potential substitutions for substances that may lose access
• Prepare patient communication materials for each possible outcome
• Document rationale for current prescribing in patient records
• Ensure your compounding partners are similarly prepared

 

Key Takeaways

• PCAC meetings shape the compounding landscape for peptide practice.
• The July 2026 cycle is the next major regulatory inflection point following the April action.
• Physician engagement — through written comment, associations, or direct participation — is a legitimate part of the process.
• Practice preparation for potential outcomes reduces clinical disruption.
• Tracking the process is increasingly a routine part of peptide-informed practice.

 

Frequently Asked Questions

What is PCAC?

The Pharmacy Compounding Advisory Committee, an FDA advisory body that evaluates substances for inclusion on the 503A bulk drug substances list.

Can physicians submit comments to PCAC?

Yes. Public comment periods exist for each substance under review. Written and, in some cases, spoken testimony are accepted.

When is the next PCAC meeting?

Meeting schedules are published on the FDA website. The July 2026 cycle is the next major meeting following the April 2026 action.

How does PCAC affect my practice?

Its recommendations, which FDA typically follows, determine what peptide substances are legally accessible through 503A compounding.

Contact Us